Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model
Pancreatic cancer (PaCa) suffers from poor treatment options for locally advanced cases. Chemophototherapy (CPT) is an emerging anti-tumor modality, and porphyrin–phospholipid liposomes have been shown to be versatile drug carriers for CPT in preclinical rodent models. Here we show that in the synge...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIP Publishing LLC
2022-09-01
|
| Series: | APL Bioengineering |
| Online Access: | http://dx.doi.org/10.1063/5.0099811 |
| _version_ | 1817980686078836736 |
|---|---|
| author | Sanjana Ghosh Xuedan He Wei-Chiao Huang Jonathan F. Lovell |
| author_facet | Sanjana Ghosh Xuedan He Wei-Chiao Huang Jonathan F. Lovell |
| author_sort | Sanjana Ghosh |
| collection | DOAJ |
| description | Pancreatic cancer (PaCa) suffers from poor treatment options for locally advanced cases. Chemophototherapy (CPT) is an emerging anti-tumor modality, and porphyrin–phospholipid liposomes have been shown to be versatile drug carriers for CPT in preclinical rodent models. Here we show that in the syngeneic subcutaneous KPC PaCa tumor model, exhausted CD8+ T cells are localized in the tumor, and that CPT is enhanced in combination with immune checkpoint blockade (ICB). Addition of ICB using anti-programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies resulted in ablation of medium-sized, established KPC tumors (∼200 mm3) without recurrence for over 100 days. Mice rejected subsequent tumor re-challenge. Flow cytometry and tumor slice analysis following injection of a fluorescently labeled anti-PD-1 antibody showed that CPT improved antibody delivery to the tumor microenvironment. Treatment of large established tumors (∼400 mm3) using with CPT and ICB induced appreciable tumor regression and delay in regrowth. Taken together, these data demonstrate the utility of combining CPT with immunotherapies. |
| first_indexed | 2024-04-13T22:56:27Z |
| format | Article |
| id | doaj.art-3b67ba2b91b1433fbe28dfc64f6e5be5 |
| institution | Directory Open Access Journal |
| issn | 2473-2877 |
| language | English |
| last_indexed | 2024-04-13T22:56:27Z |
| publishDate | 2022-09-01 |
| publisher | AIP Publishing LLC |
| record_format | Article |
| series | APL Bioengineering |
| spelling | doaj.art-3b67ba2b91b1433fbe28dfc64f6e5be52022-12-22T02:25:59ZengAIP Publishing LLCAPL Bioengineering2473-28772022-09-0163036105036105-1010.1063/5.0099811Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor modelSanjana Ghosh0Xuedan He1Wei-Chiao Huang2Jonathan F. Lovell3Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, USADepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, USADepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, USADepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, USAPancreatic cancer (PaCa) suffers from poor treatment options for locally advanced cases. Chemophototherapy (CPT) is an emerging anti-tumor modality, and porphyrin–phospholipid liposomes have been shown to be versatile drug carriers for CPT in preclinical rodent models. Here we show that in the syngeneic subcutaneous KPC PaCa tumor model, exhausted CD8+ T cells are localized in the tumor, and that CPT is enhanced in combination with immune checkpoint blockade (ICB). Addition of ICB using anti-programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies resulted in ablation of medium-sized, established KPC tumors (∼200 mm3) without recurrence for over 100 days. Mice rejected subsequent tumor re-challenge. Flow cytometry and tumor slice analysis following injection of a fluorescently labeled anti-PD-1 antibody showed that CPT improved antibody delivery to the tumor microenvironment. Treatment of large established tumors (∼400 mm3) using with CPT and ICB induced appreciable tumor regression and delay in regrowth. Taken together, these data demonstrate the utility of combining CPT with immunotherapies.http://dx.doi.org/10.1063/5.0099811 |
| spellingShingle | Sanjana Ghosh Xuedan He Wei-Chiao Huang Jonathan F. Lovell Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model APL Bioengineering |
| title | Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model |
| title_full | Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model |
| title_fullStr | Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model |
| title_full_unstemmed | Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model |
| title_short | Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model |
| title_sort | immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model |
| url | http://dx.doi.org/10.1063/5.0099811 |
| work_keys_str_mv | AT sanjanaghosh immunecheckpointblockadeenhanceschemophototherapyinasyngeneicpancreatictumormodel AT xuedanhe immunecheckpointblockadeenhanceschemophototherapyinasyngeneicpancreatictumormodel AT weichiaohuang immunecheckpointblockadeenhanceschemophototherapyinasyngeneicpancreatictumormodel AT jonathanflovell immunecheckpointblockadeenhanceschemophototherapyinasyngeneicpancreatictumormodel |